WallStSmart

Akebia Ther (AKBA)vsTeva Pharma Industries Ltd ADR (TEVA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 7765% more annual revenue ($17.23B vs $219.06M). TEVA leads profitability with a 2.9% profit margin vs -13.5%. TEVA earns a higher WallStSmart Score of 42/100 (D).

AKBA

Avoid

24

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 3.0
Piotroski: 3/9Altman Z: -5.33

TEVA

Hold

42

out of 100

Grade: D

Growth: 2.7Profit: 6.0Value: 4.3Quality: 3.5
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AKBA0 strengths · Avg: 0/10

No standout strengths identified

TEVA2 strengths · Avg: 8.5/10
Market CapQuality
$50.14B9/10

Large-cap with strong market position

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

Areas to Watch

AKBA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$195.78M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-74.9%2/10

ROE of -74.9% — below average capital efficiency

TEVA4 concerns · Avg: 2.5/10
Return on EquityProfitability
6.3%3/10

ROE of 6.3% — below average capital efficiency

Profit MarginProfitability
2.9%3/10

2.9% margin — thin

P/E RatioValuation
99.9x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : AKBA

AKBA has a balanced fundamental profile.

Bull Case : TEVA

The strongest argument for TEVA centers on Market Cap, Operating Margin. PEG of 1.04 suggests the stock is reasonably priced for its growth.

Bear Case : AKBA

The primary concerns for AKBA are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.16 is elevated, increasing financial risk.

Bear Case : TEVA

The primary concerns for TEVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 99.9x leaves little room for execution misses. Debt-to-equity of 2.13 is elevated, increasing financial risk.

Key Dynamics to Monitor

AKBA profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

TEVA carries more volatility with a beta of 0.84 — expect wider price swings.

TEVA is growing revenue faster at -1.9% — sustainability is the question.

TEVA generates stronger free cash flow (121M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (42/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akebia Ther

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?